ArticleCureus2025
The WATCHMAN Device Is a Promising Solution for Stroke Prevention in Non-Valvular Atrial Fibrillation: Challenges and Future Directions in South and Southeast Asia.
Article in Cureus, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
5 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
The WATCHMAN device (Boston Scientific Corporation, Marlborough, USA), a left atrial appendage occlusion (LAAO) device, represents a significant advancement in stroke prevention for patients with non-valvular atrial fibrillation (AFib) who are contraindicated for long-term anticoagulation therapy. By sealing the left atrial appendage (LAA), the device reduces the risk of thromboembolic events, offering an alternative to traditional anticoagulants like warfarin and direct oral anticoagulants (DOACs). Despite its proven efficacy in clinical trials, such as perforation-reducing outcomes for transcatheter endocardial closing technology (PROTECT-AF) and proactive risk evaluation validation and integrated lifecycle (PREVAIL), the adoption of the WATCHMAN device in South and Southeast Asia faces significant challenges. High procedural costs, limited healthcare infrastructure, inadequate insurance coverage, and a lack of specialized training for interventional cardiologists hinder its widespread use. Additionally, the prevalence of AFib in these regions, though lower than in Western populations, is rising, necessitating innovative solutions for stroke prevention. This article explores the barriers to WATCHMAN Device adoption in South and Southeast Asia, including cost, accessibility, and awareness, while proposing future directions such as local manufacturing, government subsidies, and enhanced training programs. Multicenter studies, public awareness campaigns, and collaboration between healthcare stakeholders are essential to improve access and outcomes. By addressing these challenges, the WATCHMAN device can play a pivotal role in reducing stroke risk and improving the quality of life for AFib patients in these regions.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.